The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

por Tanaka, Kazuki, Adams, Brigitte, Aris, Alvaro Madrid, Fujita, Naoya, Ogawa, Masayo, Ortiz, Stephan, Vallee, Marc, Greenbaum, Larry A.
Publicado 2020

Development and validation of a modified performance-oriented mobility assessment tool for assessing mobility in children with hypophosphatasia

por Phillips, Dawn, Griffin, Donna, Przybylski, Tracy, Morrison, Erica, Reeves, Amy L., Vallee, Marc, Fujita, Kenji P., Madson, Katherine L.
Publicado 2018